We are investigating the proposed merger of Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) (“Reneo”) with privately held OnKure, Inc. (“OnKure”) in a stock-for-stock transaction under which Reneo shareholders will only own approximately 31% of the combined company.
If you remain a Reneo shareholder and have concerns about the transaction, you may contact our firm to discuss your legal rights at no charge by completing and submitting the form below.
Why is there an investigation?
On May 13, 2024, Reneo announced that it had agreed to merge with OnKure in a stock-for-stock transaction under which Reneo shareholders will only own approximately 31% of the combined company.
“We are investigating whether the Reneo Board of Directors acted in the best interests of Reneo shareholders in approving the sale.” explained Joshua Fruchter, a founding partner of Wohl & Fruchter. “This includes whether the percentage of the combined company allocated to Reneo shareholders is fair, and whether all material information regarding the transaction has been fully disclosed.”